spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  fluoxetine 

 HSMN NewsFeed - 30 May 2019
U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA(R) (gilteritinib)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Aug 2010
Euthymics Bioscience, Inc. Appoints Industry Veterans Dr. Pierre Trân, Joan Manthis and William Pappafotopoulos to Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Feb 2010
Forest Laboratories Receives Decision from FDA for Supplemental New Drug Application for Bystolic(R)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 20 Jan 2010
Medco to Advance Cancer Care with Personalized and Specialized Treatment for Oncology Patients
Biopharmaceuticals Personalized Medicine Oncology
 HSMN NewsFeed - 4 Dec 2009
US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Apr 2009
Aplenzin(TM), the Only Single Tablet Once-Daily Treatment for Depression at All Doses, Now Available in the United States
Biopharmaceuticals
 HSMN NewsFeed - 23 Mar 2009
FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Dec 2008
Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Nov 2008
Mylan Receives Final FDA Approval for the Generic Version of the Antidepressant Sarafem(R) Pulvules(R) Capsules
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 7 Apr 2008
Endo Pharmaceuticals Provides Updates on FROVA(R) and CHRONOGESIC(R) Clinical Development Programs
Biopharmaceuticals
 HSMN NewsFeed - 18 Jan 2008
In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
Biopharmaceuticals
 HSMN NewsFeed - 20 Nov 2007
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Oct 2007
Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
Biopharmaceuticals
 HSMN NewsFeed - 17 Jul 2007
ABILIFY(R) (aripiprazole) Supplemental New Drug Application Receives Priority Review by U.S. Food And Drug Administration for Adjunctive Treatment in Adults With Major Depressive Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Jun 2007
Barr and Eli Lilly Voluntarily Dismiss Patent Litigation on Prozac(R) Weekly(TM)
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 30 May 2007
Mylan Announces Final FDA Approval for Fluoxetine Capsules USP, 40 mg
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 21 Feb 2007
Sepracor Announces Publication of Additional Data from Lunesta(R) Insomnia-Depression Study in the Journal of Clinical Sleep Medicine
Biopharmaceuticals
 HSMN NewsFeed - 12 Dec 2006
ABILIFY(R) (Aripiprazole) Injection for Intramuscular Use for Adults With Agitation Associated With Schizophrenia or Bipolar Mania Now Available
Biopharmaceuticals
 HSMN NewsFeed - 7 Dec 2006
ABILIFY(R) (aripiprazole) Demonstrated Efficacy as Long-Term Maintenance Therapy in Adults With Bipolar I Disorder Following Treatment for a Recent Manic Or Mixed Episode
Biopharmaceuticals
 HSMN NewsFeed - 23 Jun 2006
Sepracor Announces Presentation of LUNESTA(TM) Data at Associated Professional Sleep Societies 20th Anniversary Meeting
Biopharmaceuticals
 HSMN NewsFeed - 25 May 2006
Six-Month Study Evaluated Effectiveness of Aripiprazole and Standard of Care In Management of Community-Treated Patients with Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 23 May 2006
New Study Reports Venlafaxine Extended Release May Help Adult Patients Prevent New Episodes of Depression for Up to Two Years
Biopharmaceuticals
 HSMN NewsFeed - 23 May 2006
New Study Suggests Symbyax(R) Significantly Improves Symptoms of Treatment-Resistant Depression
Biopharmaceuticals
 HSMN NewsFeed - 22 May 2006
New Studies Examine SEROQUEL(R) in Combination With Antidepressant Therapy in Patients With Depression
Biopharmaceuticals
 HSMN NewsFeed - 22 May 2006
First Head-to-Head Study Suggests Significantly Greater Symptom Improvement for Symbyax(R) Compared to Lamotrigine in Bipolar Depression
Biopharmaceuticals
 HSMN NewsFeed - 16 May 2006
ABILIFY(R) (Aripiprazole) Demonstrated Efficacy as Maintenance Therapy In Adults with Bipolar I Disorder Following Treatment for a Recent Manic or Mixed Episode
Biopharmaceuticals
 HSMN NewsFeed - 11 May 2006
Barr Challenging Patents Protecting Prozac(R) Weekly(TM)
Biopharmaceuticals Generics Litigation
Return to NewsFeed  

 Additional items found! 32

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 32 additional stories matching:
fluoxetine
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.